| 引用本文: | 张雷,李青松,黄豫.基于真实世界研究的丹参酮ⅡA磺酸钠注射液治疗冠心病患者合并用药分析[J].中国现代应用药学,2020,37(11):1370-1374. |
| ZHANG Lei,LI Qingsong,HUANG Yu.Analysis of Combined Use of Sodium Tanshinone ⅡA Sulfonate Injection in Patients with Coronary Heart Disease Based on Real World Research[J].Chin J Mod Appl Pharm(中国现代应用药学),2020,37(11):1370-1374. |
|
| 摘要: |
| 目的 分析使用丹参酮ⅡA磺酸钠注射液治疗冠心病患者的合并用药规律。方法 选取昆山市中医医院信息系统中使用过丹参酮ⅡA磺酸钠注射液的冠心病患者的用药信息，利用频数统计和关联规则方法，对高频次药物和与丹参酮ⅡA磺酸钠注射液的联合用药情况进行评价。结果 在临床真实世界，使用丹参酮ⅡA磺酸钠注射液冠心病患者中，平均用药中位数为7种；主要单种联合用药有阿司匹林肠溶片（频率73.94%）、前列地尔注射液（频率45.28%）、阿托伐他汀钙片（频率42.35%）等；除阿司匹林肠溶片外，其余2种联合用药常用组合主要为阿托伐他汀钙片+氢氯吡格雷片（支持度55.331%）、氢氯吡格雷片+依达拉奉注射液（支持度42.279%）等；多项合并用药关联分析表明，丹参酮ⅡA磺酸钠注射液治疗冠心病多与阿司匹林肠溶片、泮托拉唑注射液、氢氯吡格雷片、阿托伐汀钙片和依达拉奉注射液一起合并使用。结论 丹参酮ⅡA磺酸钠注射液在治疗冠心病患者时基本符合指南要求，但应关注功效相似药物或中西药联合使用时的获益与风险，降低配伍伤害。 |
| 关键词: 真实世界 丹参酮ⅡA磺酸钠注射液 合并用药 冠心病 关联规则 |
| DOI：10.13748/j.cnki.issn1007-7693.2020.11.016 |
| 分类号:R969.4 |
| 基金项目:苏州市药学会-常州四药临床药学科研基金/苏州市2018年度科技发展计划（SYSD2018223） |
|
| Analysis of Combined Use of Sodium Tanshinone ⅡA Sulfonate Injection in Patients with Coronary Heart Disease Based on Real World Research |
|
ZHANG Lei, LI Qingsong, HUANG Yu
|
|
Department of Pharmacy, Traditional Chinese Medicine Hospital of Kunshan, Kunshan 215300, China
|
| Abstract: |
| OBJECTIVE To analyze the rules of medicinal groups that doctors treat patients with coronary heart disease using sodium tanshinone ⅡA sulfonate injection. METHODS Drug information of patients with coronary heart disease who used sodium tanshinone ⅡA sulfonate injection from hospital information system of Traditional Chinese Medicine Hospital of Kunshan were collected. Then used frequency statistics and association rules to evaluate the high-frequency drugs and sodium tanshinone ⅡA sulfonate injection combined medication. RESULTS In clinical real world use, the patients with coronary heart disease treated with tanshinone ⅡA sodium sulfonate injection, and the average median of drug use was 7 kinds. The main single combination drugs were aspirin enteric-coated tablets(73.94%), alprostadil injection(45.28%), atorvastatin calcium tablets(42.35%) and so on. In addition to aspirin enteric tablets, the other two commonly used combinations were atorvastatin calcium tablets+hydroclopidogrel tablets(55.331%) and hydroclopidogrel tablets+edaravone injection(42.279%). The correlation analysis of multiple combined drug use showed that sodium tanshinone ⅡA sulfonate injection was used in the treatment of coronary heart disease with aspirin enteric-coated tablets, pantoprazole sodium injection, hydroclopidogrel tablets, atorvastatin calcium tablets and edaravone injection. CONCLUSION Sodium tanshinone ⅡA sulfonate injection in the treatment of coronary heart disease patients with basic conform to the requirements of the guidelines. However, attention shall be paid to the benefits and risks of drugs with similar efficacy or the combination of Chinese and western medicines, so as to reduce the compatibility harm. |
| Key words: real world sodium tanshinone ⅡA sulfonate injection drug combination coronary heart disease association rules |
